Abstract

Background: Acute Hepatitis B has a low chronification rate in healthy adults, but can progress to fulminant hepatitis and liver failure in about 1 percent. Our aim was to evaluate the efficacy and safety of tenofovir as first-line treatment for patients with severe and progressive acute hepatitis B.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call